Clinical trial · Interventional
Identifying Prostate Brachytherapy Seeds Using MRI
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will look at the feasibility of using a type of Magnetic Resonance Imaging called Susceptibility Weighted Imaging (SWI) to detect your implanted radioactive seeds. Researchers hope that using SWI will eliminate the need to use CT imaging to detect your implanted radioactive seeds. This study will also see if the MRI seed detection is as effective as current standard practice of seed detection (routine MRI and CT imaging). This technique would be beneficial for brachytherapy without the need to fuse the MRI and CT images, as is done currently.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Patients Who Have Brachytherapy Seed Implant | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI Scan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- MRI Scan
- description
- Patients will receive an extra MRI scan in addition to their routine scan.
- interventionNames
- Other: MRI Scan
Primary outcomes (3)
- measure
- Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce registration errors
- timeFrame
- 6 months
- measure
- Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce planning time for the post-implant plan
- timeFrame
- 6 months
- measure
- Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will eliminate the CT scan of the patient.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. At least 18 years old 2. Histologic diagnosis of adenocarcinoma of the prostate 3. No contraindications for Pelvic body MRI 4. Patients undergoing LDR brachytherapy at PMH and scheduled for post implant analysis with CT-MR (standard at PMH) 5. Ability to provide written informed consent to participate in the study Exclusion Criteria: 1. Contraindication for Pelvic body MRI 2. Patient not willing/consenting for this study
References
Publications (0)
Data not yet available